The BLA could be resubmitted but it would take going back to primary sources and collecting all the data. Then compiling all that data again for a difficult to do BLA since it uses data from two different trials. Given that the FDA is asking for a new HIV trial protocol they may reject that BLA submission out of hand without even looking at it.